Assignee
MICROMET AG
DE·20 granted patents·9 pending applications·1,450 citations·filing 1993–2009
Top patents by PatentIndex Score
29 records- 0197US7820166B2Potent T cell modulating moleculesMICROMET AG·Filed 2003·Granted Oct 26, 2010·94 cites·30 claims
- 0297US7235641B2Bispecific antibodiesMICROMET AG·Filed 2003·Granted Jun 26, 2007·167 cites·2 claims
- 0396US8007796B2Means and methods for the treatment of tumorous diseasesMICROMET AG·Filed 2006·Granted Aug 30, 2011·69 cites·18 claims
- 0496US7635472B2Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disordersMICROMET AG·Filed 2004·Granted Dec 22, 2009·158 cites·8 claims
- 0595US7575923B2CD19xCD3 specific polypeptides and uses thereofMICROMET AG·Filed 2006·Granted Aug 18, 2009·103 cites·4 claims
- 0694US7632925B2Antibodies that bind human 17-A1/EpCAM tumor antigenMICROMET AG·Filed 2007·Granted Dec 15, 2009·17 cites·10 claims
- 0794US7112324B1CD 19×CD3 specific polypeptides and uses thereofMICROMET AG·Filed 1999·Granted Sep 26, 2006·219 cites·23 claims
- 0892US8017748B2Antibody neutralizers of human granulocyte macrophage colony stimulating factorMICROMET AG·Filed 2006·Granted Sep 13, 2011·56 cites·20 claims
- 0992US7919089B2Pharmaceutical composition comprising a bispecific antibody for EpCAMMICROMET AG·Filed 2004·Granted Apr 5, 2011·57 cites·3 claims
- 1092US6723538B2Bispecific antibody and chemokine receptor constructsMICROMET AG·Filed 2001·Granted Apr 20, 2004·149 cites·11 claims
- 1191US7332168B2Composition for the elimination of autoreactive B-cellsMICROMET AG·Filed 2001·Granted Feb 19, 2008·42 cites·2 claims
- 1288US7323440B2De-immunized MOG (poly)peptide constructsMICROMET AG·Filed 2003·Granted Jan 29, 2008·41 cites·8 claims
- 1388US7229760B2mRNA amplificationMICROMET AG·Filed 2001·Granted Jun 12, 2007·72 cites·40 claims
- 1483US7976842B2Treatment of metastatic breast cancerMICROMET AG·Filed 2007·Granted Jul 12, 2011·7 cites·6 claims
- 1582US7435549B1Method of identifying binding site domains that retain the capacity of binding to an epitopeMICROMET AG·Filed 1998·Granted Oct 14, 2008·51 cites·47 claims
- 1682US7227002B1Human antibodies that bind human 17-A1/EpCAM tumor antigenMICROMET AG·Filed 1998·Granted Jun 5, 2007·52 cites·10 claims
- 1778US6673541B1DNA amplification of a single cellMICROMET AG·Filed 1999·Granted Jan 6, 2004·92 cites·30 claims
- 1871US7964707B2Anti-IL2 antibodiesMICROMET AG·Filed 2006·Granted Jun 21, 2011·2 cites·19 claims
- 1963US2010183615A1Cross-species-specific bispecific bindersMICROMET AG·Filed 2008·Application pending·0 cites
- 2060US2011262440A1Treatment of pediatric acute lymphoblastic leukemiaMICROMET AG·Filed 2009·Application pending·0 cites
- 2158US2003148463A1Novel method for the production of anti-human antigen receptors and uses thereofMICROMET AG·Filed 2002·Application pending·0 cites
- 2254US2009226444A1Pharmaceutical antibody compositions with resistance to soluble ceaMICROMET AG·Filed 2006·Application pending·0 cites
- 2349US2010150918A1Cross-species-specific binding domainMICROMET AG·Filed 2008·Application pending·0 cites
- 2445US2007122852A1Method for identifying antigen specific b cellsMICROMET AG·Filed 2003·Application pending·0 cites
- 2543US2009241202A1Domain-grafted antibodiesMICROMET AG·Filed 2006·Application pending·0 cites
- 2642US2005180979A1Anti-EpCAM immunoglobulinsMICROMET AG·Filed 2004·Application pending·0 cites
- 2741US2007274982A1Anti-EpCam ImmunoglobulinsMICROMET AG·Filed 2005·Application pending·0 cites
- 2832US6475727B1Primers and methods for the detection of disseminated tumor cellsMICROMET AG·Filed 1998·Granted Nov 5, 2002·2 cites·20 claims
- 2931US7105638B1Product and process for the production, isolation, and purification of recombinant polypeptideMICROMET AG·Filed 1993·Granted Sep 12, 2006·0 cites·18 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →